PhRMA earned a major win against legislation that would have stopped drugmakers from denying generic-drug companies the ability to study their products to bring low-cost competition to market. (Photo: Shutterstock)
The drug industry set several quarterly records for lobbying spending in the first three months gof 2018 as it faced pressure from President Donald Trump's administration and lawmakers on drug pricing, generic medicines and trade.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
